Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.

ABSTRACT:

Background

Molecular profiling is increasingly used to match patients with metastatic cancer to targeted therapies, but obtaining a high-quality biopsy specimen from metastatic sites can be difficult.

Methods

Patient samples were received by Perthera to coordinate genomic, proteomic and/or phosphoproteomic testing, using a specimen from either the primary tumour or a metastatic site. The relative frequencies were compared across specimen sites to assess the potential limitations of using a primary tumour sample for clinical decision support.

Results

No significant differences were identified at the gene or pathway level when comparing genomic alterations between primary and metastatic lesions. Site-specific trends towards enrichment of MYC amplification in liver lesio

SUBMITTER: Brar G 

PROVIDER: S-EPMC6738081 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature